Although these kinds of Th1 cytokines, including IL-12, TNF-α, and IFN-γ, are promising in cancer immunotherapy, their clinical application is associated with short half-life, narrow therapeutic window, severe dose-limiting toxicities, and difficulties in large-scale manufacturing (31). This evidence concerns the gene TNF and cancer.